Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Attenuated Psychosis Syndrome
Interventions: Aripiprazole, Fluoxetine; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 25 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Sialorrhea
Interventions: MYOBLOC, PLACEBO; Drug · Other
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 24
States / cities: Loma Linda, California • Los Angeles, California • National City, California + 21 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania

Conditions: Schizophrenia, Impaired Cognition
Interventions: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 38
States / cities: Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more

Conditions: Patient Noncompliance
Interventions: haloperidol decanoate, haloperidol, Customized Adherence Enhancement; Drug · Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Antipsychotic Agents, Bipolar Disorder
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Schizophrenia
Interventions: multifamily group-adherence, multifamily group-standard; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Granada Hills, California

Conditions: Schizophrenia and Schizoaffective Disorder
Interventions: Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 63
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 54 more

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine, Quetiapine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Anorexia Nervosa
Interventions: Risperidone, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions: Haloperidol, Ziprasidone, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 16
States / cities: Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more

Conditions: Schizophrenia
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Garden Grove, California + 16 more

Conditions: Schizophrenia
Interventions: ITI-007, Placebo, Risperidone; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: Little Rock, Arkansas • Garden Grove, California • Atlanta, Georgia + 5 more

Conditions: Schizophrenia
Interventions: Individual Placement and Support (Supported Employment), Social Skills Training, Olanzapine, Risperidone; Behavioral · Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 2
States / cities: Los Angeles, California • Manchester, New Hampshire

Conditions: Schizophrenia
Interventions: ANAVEX3-71 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Anavex Life Sciences Corp.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Schizophrenia, Alzheimer's Disease, Dementia
Interventions: Aripiprazole, Olanzapine, Risperidone; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years and older
Enrollment: 406 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Schizophrenia
Interventions: Quetiapine, Risperidone, Fluphenazine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Schizophrenia
Interventions: Metformin, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 16
States / cities: Palo Alto, California • Boca Raton, Florida • Iowa City, Iowa + 13 more

Conditions: Schizophrenia
Interventions: CT-156-C-001; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Mental Disorders
Interventions: Testing (MRS, US, DEXA, blood tests); Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 66 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions: EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: PTSD, Post-Traumatic Stress Disorder
Interventions: Not listed
Lead sponsor: Tuscaloosa Research & Education Advancement Corporation; Other
Eligibility: 19 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Search by objective public record fields.

Fluoxetine vs Aripiprazole Comparative Trial (FACT)

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Pharmacoepigenetics of Bipolar Disorder Treatment

Promoting Adherence to Treatment in Schizophrenia

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Antipsychotic Response in Schizophrenia

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

A Study of ANAVEX3-71 in Adults With Schizophrenia

Side Effects of Newer Antipsychotics in Older Adults

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children

Side Effects of Antipsychotic Medications

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years